BioCentury
ARTICLE | Clinical News

ATI-5923: Phase II data

November 24, 2008 8:00 AM UTC

In an open-label Phase II trial, ATI-5923 produced stable control of anticoagulation for a mean TTR of 72%. Stable control was achieved for a mean TTR of 59% in patients who had previously received wa...